- In December 2024, Labcorp, a global leader in laboratory services, announced the commercial launch of its new H5 bird flu molecular test, designed to assist in diagnosing human infections with the H5N1 virus. This test is now available for physicians in the United States to order for patients suspected of having H5N1
- In July 2024, Twist Bioscience Corporation, a pioneer in high-quality synthetic DNA production using its silicon platform, expanded its synthetic viral controls portfolio by launching a synthetic RNA control for H5N1 Influenza A. This control covers 99.9% of the hemagglutinin (HA) and neuraminidase (NA) genome regions, addressing one of the causes of Highly Pathogenic Avian Influenza (HPAI), also known as bird flu
- In June 2024, Integrated DNA Technologies introduced new primers and a probe set for identifying H5N1 Avian Influenza. This PCR/qPCR solution aims to support surveillance and monitoring of the current H5N1 bird flu strain, responding to a multi-state outbreak in U.S. dairy cows
